GABAB receptor mediates slow and prolonged synaptic inhibition in the central nervous system, which represents an interesting target for the treatment of various CNS diseases and disorders. Till now, only one activator of GABAB receptor, baclofen, is on the market for the treatment of spasticity. Inhibitors of GABAB receptor such as antagonists show anti-absence seizure activity and pro-cognitive properties. In a search for the allosteric compounds of GABAB receptor, whereas several positive allosteric modulators (PAMs) have been developed, only recently the first negative allosteric modulator (NAM), CLH304a (also named as Compound 14), has been reported. Here we provide further information on the mechanism of action of CLH304a, and also show the possibility to design more NAMs such asCLH391 and CLH393, based on the structure of CLH304a. We first show that CLH304a inhibits the native GABAB receptor activity in cultured cerebellar granule neurons. We then show that CLH304a has inverse agonist property and non-competitively inhibits the effect of agonist, indicating that it binds at a different site than GABA. GABAB receptor is a mandatory heterodimer made of GB1subunits where agonists bind, and GB2 subunits that activates G proteins. By using various combinations made of wild type and/or mutated of GB1 and GB2, we show that CLH304a acts on the heptahelical domain of GB2. These data revealed the possibility to design innovative NAMs acting in the HD of GB2, offering novel possibilities for therapeutic intervention based on GABAB receptor inhibition.